Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of Mitoxantrone Liposome in Recurrent/Refractory Lymphoma
NCT05173545Phase 1Completed
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology
- Start
- Jul 2019
- Primary completion
- Oct 2020
- Modality
- Targeted Liposomes, Stealth (PEGylated) Liposomes, Conventional Liposomes
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of mitoxantrone hydrochloride liposome in lymphoma (3 arms), sponsored by CSPC ZhongQi Pharmaceutical Technology. Primary endpoints: Maximum concentration at 28 days, Time to maximum concentration at 28 days and 1 more. Started Jul 2019; status: completed.
02
Drugs
mitoxantrone hydrochloride liposome
03
Conditions
lymphoma
Beyond the preview
Go deeper on NCT05173545.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05173545.